EKG — CardioComm Solutions — heads into its May 1 results with short interest at a multi-month high and insider transaction data too stale to be meaningful.
The most notable development this week is the sharp rise in shares sold short. Short interest has climbed nearly 9x since late March — from 258 shares to 2,289 — with the jump concentrated in two discrete steps: first in early April (to 1,489 shares) and then again around April 20 (to 2,289 shares, where it remains). That's an 800% rise over the month. Context matters here: the absolute share count is tiny relative to any normal measure of float, and no free-float percentage can be calculated, which limits how alarming the absolute move looks. Still, the directional signal is unambiguous — someone has been incrementally building a short position in the days leading up to the earnings release.
The borrow market tells a relaxed story, however. Availability is near the loosest end of the spectrum — only a fraction of the available lending pool has been drawn on. The ORTEX short score is just 25, near the bottom of the range, and the short score rank of 98 reflects that relative to the broader universe, very few shares are on loan here. Cost-to-borrow data is stale (last reading March 25 at 0.64%), so no firm conclusion can be drawn on borrow pressure — but the low utilization of the lending pool suggests no squeeze dynamics are building.
Concentration is the sharpest feature of the ownership picture. The Grima family — Daniel and Etienne — together hold roughly 26% of the company, with Etienne's position last reported as unchanged on April 26. A second holder, Md Primer Inc., accounts for another 16%. Together the top two holders control around 42% of the share count. Fresh institutional activity is minimal; ITF Ventures reported adding 65,600 shares as of April 6 — a small position relative to the total. Insider transaction data is unavailable from the past several years (the most recent trade on record dates to early 2019), so no read on recent executive sentiment is possible.
The backdrop for the sector is constructive on paper. A mid-April industry report projected the global wearable ECG monitor market to more than double between 2026 and 2030, potentially exceeding $13.6 billion in revenue, driven by AI-driven diagnostics and home cardiac monitoring adoption. CardioComm's core business sits squarely in that growth narrative. Analyst coverage, valuation multiples, and factor scores beyond the short-side are unavailable in current data, and the company's market capitalisation is not reported — all of which points to the thin, micro-cap profile typical of TSXV-listed health-tech names at this price level (C$0.01 per share, unchanged on the week).
The May 1 earnings release is the immediate focal point. The prior four results all registered zero one-day and five-day price moves in the data — a pattern that may reflect illiquidity rather than genuine stability, given the $0.01 share price. How the stock reacts to the next print, particularly in the context of a short position that has grown sharply in the run-up, is the live question from here.
See the live data behind this article on ORTEX.
Open EKG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
